Drug Profile
UV 1
Alternative Names: UV-1; UV1 synthetic peptide vaccine; UV1 vaccineLatest Information Update: 26 Mar 2024
Price :
$50
*
At a glance
- Originator Norwegian Radium Hospital; Ultimovacs AS
- Developer Arbeitsgemeinschaft Internistische Onkologie; AstraZeneca; Bristol-Myers Squibb; European Network of Gynaecological Oncological Trial Groups; Hellenic Cooperative Oncology Group; Nordic Society of Gynaecological - Clinical Trial Unit; North Eastern German Society of Gynaecological Oncology; Oslo University Hospital; Ultimovacs AS; Vestre Viken Hospital Trust; Working Group for Gynecological Oncology
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Head and neck cancer; Malignant melanoma; Malignant-mesothelioma; Non-small cell lung cancer; Ovarian cancer
- Phase I/II Prostate cancer
Most Recent Events
- 21 Mar 2024 9412909 - added patent info and HEs (downloaded Annual report 2023 for reference)
- 21 Mar 2024 Ultimovacs has patent pending for UV 1 in combination with an immune checkpoint inhibitor and anti-CTLA-4 and/or anti-PD(L)-1 antibodies in Europe, Japan, Australia and Canada
- 21 Mar 2024 Ultimovacs has patent protection for UV 1 composition of matter in Europe, USA, Japan, Russia, South Korea, India, China and Hong Kong